Amalya Sargsyan: DestinyGastric03 trial results and HER2+ treatment insights at ESMO24

Amalya Sargsyan posted the following on X:

“Great insights from Yelena Janjigian, MD at ESMO24! The latest results from the DestinyGastric03 trial, exploring T-DXd mono & combos for advanced HER2+ Gastric/E/GEJ cancers. And eye-opening talk on systemic tx approaches and why biology, not location, is key for tx for G/GEJ cancers.”

Source: Amalya Sargsyan/X

r. Amalya Sargsyan is a Medical Oncologist at Yeolyan Center,  a Research Physician at the Immune Oncology Research Institute, and Senior Editor at Oncodaily. She holds an MD from Yerevan State Medical University and an MSc in Precision Medicine from the University of Cyprus.

Dr. Sargsyan completed her clinical training at the Bank of Cyprus Oncology Center and has been honored with an ASCO IDEA award.  Her research focuses on the potential of novel immune checkpoint inhibitors (ICI) in low- and middle-income countries (LMICs), aiming to bridge disparities and enhance access to innovative cancer care.